BLPH vs. SXTC, ADTX, ALLR, EVFM, EVLO, SPRC, AMPE, APVO, ATHX, and CALA
Should you be buying Bellerophon Therapeutics stock or one of its competitors? The main competitors of Bellerophon Therapeutics include China SXT Pharmaceuticals (SXTC), Aditxt (ADTX), Allarity Therapeutics (ALLR), Evofem Biosciences (EVFM), Evelo Biosciences (EVLO), SciSparc (SPRC), Ampio Pharmaceuticals (AMPE), Aptevo Therapeutics (APVO), Athersys (ATHX), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical preparations" industry.
China SXT Pharmaceuticals (NASDAQ:SXTC) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation, community ranking and dividends.
China SXT Pharmaceuticals has higher revenue and earnings than Bellerophon Therapeutics.
Bellerophon Therapeutics' return on equity of 0.00% beat China SXT Pharmaceuticals' return on equity.
China SXT Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Bellerophon Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.
Bellerophon Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 3,536.36%. Given China SXT Pharmaceuticals' higher probable upside, analysts clearly believe Bellerophon Therapeutics is more favorable than China SXT Pharmaceuticals.
In the previous week, Bellerophon Therapeutics had 1 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 2 mentions for Bellerophon Therapeutics and 1 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 0.69 beat Bellerophon Therapeutics' score of -1.00 indicating that Bellerophon Therapeutics is being referred to more favorably in the news media.
Bellerophon Therapeutics received 237 more outperform votes than China SXT Pharmaceuticals when rated by MarketBeat users. However, 61.65% of users gave China SXT Pharmaceuticals an outperform vote while only 60.65% of users gave Bellerophon Therapeutics an outperform vote.
5.0% of China SXT Pharmaceuticals shares are held by institutional investors. Comparatively, 10.6% of Bellerophon Therapeutics shares are held by institutional investors. 4.0% of China SXT Pharmaceuticals shares are held by company insiders. Comparatively, 5.2% of Bellerophon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
China SXT Pharmaceuticals and Bellerophon Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Bellerophon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bellerophon Therapeutics Competitors List
Related Companies and Tools
